Pfizer Starts New Study of Oral Drug for Prevention of COVID-19

A person walks past a Pfizer logo in the Manhattan borough of New York City on April 1, 2021. Carlo Allegri/Reuters

Pfizer has started a global study to explore the efficacy and safety of an oral drug meant to prevent COVID-19, the disease caused by the CCP (Chinese Communist Party) virus.

Pfizer’s Phase 2/3 study will evaluate the drug candidate in participants who live in the same household as a person who has a confirmed COVID-19 infection.